Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Malignant Melanoma

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 42 articles: HTML format

Single Articles

October 2023
1. LIU M, Dong Q, Chen B, Liu K, et al
   Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells.
   Br J Cancer. 2023;129:1339-1349.
   PubMed     Abstract available
   
   
   
2. DONINI C, Galvagno F, Rotolo R, Massa A, et al
   PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade.
   Br J Cancer. 2023;129:1409-1416.
   PubMed     Abstract available
   
   
   July 2023
3. MARIANI P, Torossian N, van Laere S, Vermeulen P, et al
   Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.
   Br J Cancer. 2023 Jul 13. doi: 10.1038/s41416-023-02331.
   PubMed     Abstract available
   
   
   March 2023
4. RODRIGUES A, Cosman R, Joshua AM
   Correction To: LXS196 for Metastatic Uveal Melanoma - finally some progress.
   Br J Cancer. 2023 Mar 28. doi: 10.1038/s41416-023-02231.
   PubMed    
   
   
   
5. RODRIGUES A, Cosman R, Joshua AM
   LXS196 for Metastatic Uveal Melanoma - finally some progress.
   Br J Cancer. 2023 Mar 1. doi: 10.1038/s41416-023-02199.
   PubMed    
   
   
   January 2023
6. PIPERNO-NEUMANN S, Carlino MS, Boni V, Loirat D, et al
   A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.
   Br J Cancer. 2023 Jan 9. doi: 10.1038/s41416-022-02133.
   PubMed     Abstract available
   
   
   December 2022
7. VAN DER KOOIJ MK, Joosse A, Suijkerbuijk KPM, Aarts MJB, et al
   Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.
   Br J Cancer. 2022 Dec 23. doi: 10.1038/s41416-022-02088.
   PubMed    
   
   
   November 2022
8. EGGER S, Smith DP, Patel MI, Kimlin MG, et al
   Cutaneous melanoma, prostate-specific antigen testing and the subsequent risk of prostate cancer diagnosis: a prospective analysis of the 45 and Up Study.
   Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02027.
   PubMed     Abstract available
   
   
   October 2022
9. BUTLER EN, Zhou CK, Curry M, McMenamin U, et al
   Testosterone therapy and cancer risks among men in the SEER-Medicare linked database.
   Br J Cancer. 2022 Oct 28. pii: 10.1038/s41416-022-02019.
   PubMed     Abstract available
   
   
   August 2022
10. JUNG S, Armstrong E, Wei AZ, Ye F, et al
    Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01942.
    PubMed     Abstract available
    
    
    July 2022
11. LI Y, Wang Q, Chen Y, Zhao L, et al
    Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors.
    Br J Cancer. 2022 Jul 23. pii: 10.1038/s41416-022-01921.
    PubMed     Abstract available
    
    
    June 2022
12. BARCELO C, Siso P, de la Rosa I, Megino-Luque C, et al
    M-CSF as a therapeutic target in BRAF(V600E) melanoma resistant to BRAF inhibitors.
    Br J Cancer. 2022 Jun 20. pii: 10.1038/s41416-022-01886.
    PubMed     Abstract available
    
    
    
13. BREST P, Refae S, Mograbi B, Ferrero JM, et al
    Checkpoint inhibitors in a marriage: consented or arranged?
    Br J Cancer. 2022;126:1834-1836.
    PubMed     Abstract available
    
    
    April 2022
14. LUNDBERG A, Li B, Li R
    B cell-related gene signature and cancer immunotherapy response.
    Br J Cancer. 2022;126:899-906.
    PubMed     Abstract available
    
    
    March 2022
15. RAMTOHUL T, Cohen A, Rodrigues M, Piperno-Neumann S, et al
    Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma.
    Br J Cancer. 2022 Mar 26. pii: 10.1038/s41416-022-01793.
    PubMed     Abstract available
    
    
    
16. KUMAR PR, Saad M, Hellmich C, Mistry JJ, et al
    PGC-1alpha induced mitochondrial biogenesis in stromal cells underpins mitochondrial transfer to melanoma.
    Br J Cancer. 2022 Mar 26. pii: 10.1038/s41416-022-01783.
    PubMed     Abstract available
    
    
    
17. WOOF VG, Lee RJ, Lorigan P, French DP, et al
    Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma.
    Br J Cancer. 2022 Mar 17. pii: 10.1038/s41416-022-01766.
    PubMed     Abstract available
    
    
    
18. VAN BREESCHOTEN J, Wouters MWJM, Hilarius DL, Haanen JB, et al
    Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis.
    Br J Cancer. 2022 Mar 7. pii: 10.1038/s41416-022-01772.
    PubMed    
    
    
    February 2022
19. BEASLEY AB, Chen FK, Isaacs TW, Gray ES, et al
    Future perspectives of uveal melanoma blood based biomarkers.
    Br J Cancer. 2022 Feb 21. pii: 10.1038/s41416-022-01723.
    PubMed     Abstract available
    
    
    November 2021
20. HAMIS SJ, Kapelyukh Y, McLaren A, Henderson CJ, et al
    Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling.
    Br J Cancer. 2021;125:1552-1560.
    PubMed     Abstract available
    
    
    October 2021
21. HASSEL JC
    Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma.
    Br J Cancer. 2021 Oct 25. pii: 10.1038/s41416-021-01390.
    PubMed     Abstract available
    
    
    August 2021
22. MARSAVELA G, McEvoy AC, Pereira MR, Reid AL, et al
    Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.
    Br J Cancer. 2021 Aug 9. pii: 10.1038/s41416-021-01507.
    PubMed     Abstract available
    
    
    July 2021
23. BOUCHEREAU S, Chaplain L, Fort M, Beauchet A, et al
    Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.
    Br J Cancer. 2021 Jul 14. pii: 10.1038/s41416-021-01486.
    PubMed     Abstract available
    
    
    June 2021
24. MAIQUES O, Fanshawe B, Crosas-Molist E, Rodriguez-Hernandez I, et al
    A preclinical pipeline to evaluate migrastatics as therapeutic agents in metastatic melanoma.
    Br J Cancer. 2021 Jun 25. pii: 10.1038/s41416-021-01442.
    PubMed     Abstract available
    
    
    May 2021
25. WEBER A, Leitzmann MF, Sedlmeier AM, Baurecht H, et al
    Association between physical activity, grip strength and sedentary behaviour with incidence of malignant melanoma: results from the UK Biobank.
    Br J Cancer. 2021 May 31. pii: 10.1038/s41416-021-01443.
    PubMed     Abstract available
    
    
    April 2021
26. DHOMEN N, Mundra PA, Marais R
    Sunglasses to hide behind may also prevent melanoma of the eyes.
    Br J Cancer. 2021 Apr 6. pii: 10.1038/s41416-021-01343.
    PubMed     Abstract available
    
    
    
27. WANG H, Elsheikh M, Gilmour K, Cohen V, et al
    Impact of COVID-19 pandemic on eye cancer care in United Kingdom.
    Br J Cancer. 2021;124:1357-1360.
    PubMed     Abstract available
    
    
    March 2021
28. VAN BREESCHOTEN J, Wouters MWJM, Hilarius DL, Haanen JB, et al
    Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01312.
    PubMed    
    
    
    
29. YE W, Olsson-Brown A, Watson RA, Cheung VTF, et al
    Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01310.
    PubMed     Abstract available
    
    
    
30. YAO S, Janku F, Subbiah V, Stewart J, et al
    Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
    Br J Cancer. 2021 Mar 5. pii: 10.1038/s41416-020-01230.
    PubMed     Abstract available
    
    
    
31. KATO R, Haratani K, Hayashi H, Sakai K, et al
    Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts.
    Br J Cancer. 2021;124:914-924.
    PubMed     Abstract available
    
    
    February 2021
32. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available
    
    
    January 2021
33. VAN BREESCHOTEN J, Wouters MWJM, Hilarius DL, Haanen JB, et al
    First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis.
    Br J Cancer. 2021 Jan 26. pii: 10.1038/s41416-020-01229.
    PubMed     Abstract available
    
    
    December 2020
34. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available
    
    
    November 2020
35. KUMAR PR, Moore JA, Bowles KM, Rushworth SA, et al
    Mitochondrial oxidative phosphorylation in cutaneous melanoma.
    Br J Cancer. 2020 Nov 18. pii: 10.1038/s41416-020-01159.
    PubMed     Abstract available
    
    
    
36. SMITH AJ, Lambert PC, Rutherford MJ
    Understanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study.
    Br J Cancer. 2020 Nov 4. pii: 10.1038/s41416-020-01144.
    PubMed     Abstract available
    
    
    October 2020
37. BHAVE P, Pallan L, Long GV, Menzies AM, et al
    Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
    Br J Cancer. 2020 Oct 22. pii: 10.1038/s41416-020-01121.
    PubMed     Abstract available
    
    
    
38. PAMIDIMUKKALA N, Puts GS, Kathryn Leonard M, Snyder D, et al
    Nme1 and Nme2 genes exert metastasis-suppressor activities in a genetically engineered mouse model of UV-induced melanoma.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01096.
    PubMed     Abstract available
    
    
    
39. RABBIE R, Ferguson P, Wong K, Couturier DL, et al
    The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01090.
    PubMed     Abstract available
    
    
    August 2020
40. ALMEIDA RR, Vieira RS, Castoldi A, Terra FF, et al
    Host dysbiosis negatively impacts IL-9-producing T-cell differentiation and antitumour immunity.
    Br J Cancer. 2020;123:534-541.
    PubMed     Abstract available
    
    
    July 2020
41. CHEUNG VTF, Gupta T, Olsson-Brown A, Subramanian S, et al
    Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
    Br J Cancer. 2020;123:207-215.
    PubMed     Abstract available
    
    
    April 2020
42. MCNEILLIS R, Greystoke A, Walton J, Bacon C, et al
    A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.
    Br J Cancer. 2020;122:1141-1145.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.